Direct (new) oral anticoagulants (DOACs): Drawbacks, bleeding and reversal
CONCLUSION: Management recommendations for hemorrhage associated with DOAC use vary, depending on the class of the culprit agent (direct thrombin inhibitor vs. FXa inhibitor), the clinical status of the patient (mild/ moderate vs. severe/life-threatening), and capabilities of the institution. Specific reversal agents (i.e., idarucizumab and andexanet alfa) can be used if available, while prothrombin complex concentrates, fresh frozen plasma and/ or tranexamic acid can also be employed as nonspecific replacement agents in the management of DOAC-related bleeding diathesis.PMID:34521332 | DOI:10.2174/1871525719666210914110750
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - Category: Cardiology Authors: Ozgur Karcioglu Sehmus Zengin Bilgen Ozkaya Eylem Ersan Sarper Yilmaz Goksu Afacan Derya Abuska Mandana Hosseinzadeh Selman Yeniocak Source Type: research
More News: Bleeding | Cardiology | Cardiovascular | Chemistry | Clinical Trials | Coumadin | Databases & Libraries | Gastroenterology | Heart | Hematology | Liver | Overdose | Pradaxa | Respiratory Medicine | Study | Thrombosis | Urology & Nephrology | Warfarin